BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,096 filers reported holding BAXTER INTL INC in Q4 2020. The put-call ratio across all filers is 0.87 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $276 | +22.7% | 7,323 | +48.6% | 0.00% | 0.0% |
| Q2 2023 | $225 | -30.8% | 4,929 | -22.7% | 0.00% | 0.0% |
| Q4 2022 | $325 | -99.9% | 6,373 | +8.5% | 0.00% | 0.0% |
| Q3 2022 | $316,000 | -84.4% | 5,875 | -81.4% | 0.00% | -85.7% |
| Q2 2022 | $2,027,000 | -16.4% | 31,554 | +0.8% | 0.01% | -12.5% |
| Q1 2022 | $2,426,000 | -31.3% | 31,293 | -23.9% | 0.01% | -20.0% |
| Q4 2021 | $3,531,000 | +42.7% | 41,132 | +33.7% | 0.01% | +25.0% |
| Q3 2021 | $2,474,000 | +11.1% | 30,765 | +11.2% | 0.01% | +33.3% |
| Q2 2021 | $2,227,000 | -30.9% | 27,663 | -27.6% | 0.01% | -33.3% |
| Q1 2021 | $3,223,000 | -8.9% | 38,212 | -13.4% | 0.01% | -18.2% |
| Q4 2020 | $3,539,000 | -41.5% | 44,106 | -41.4% | 0.01% | -57.7% |
| Q3 2020 | $6,049,000 | -19.6% | 75,219 | -13.9% | 0.03% | -23.5% |
| Q2 2020 | $7,519,000 | +22.1% | 87,331 | +15.2% | 0.03% | +9.7% |
| Q1 2020 | $6,156,000 | -9.2% | 75,817 | -6.5% | 0.03% | +10.7% |
| Q4 2019 | $6,779,000 | -18.7% | 81,074 | -15.0% | 0.03% | -24.3% |
| Q3 2019 | $8,340,000 | +1.7% | 95,345 | -4.8% | 0.04% | +2.8% |
| Q2 2019 | $8,202,000 | +2.5% | 100,145 | +1.8% | 0.04% | -2.7% |
| Q1 2019 | $8,002,000 | -22.8% | 98,414 | -37.5% | 0.04% | -30.2% |
| Q4 2018 | $10,361,000 | -11.6% | 157,409 | +3.5% | 0.05% | +6.0% |
| Q3 2018 | $11,727,000 | +182.2% | 152,117 | +170.3% | 0.05% | +177.8% |
| Q2 2018 | $4,155,000 | +114.4% | 56,270 | +88.9% | 0.02% | +125.0% |
| Q1 2018 | $1,938,000 | +33.5% | 29,791 | +32.6% | 0.01% | +14.3% |
| Q4 2017 | $1,452,000 | -25.4% | 22,462 | -27.6% | 0.01% | -22.2% |
| Q3 2017 | $1,947,000 | -6.3% | 31,033 | -9.6% | 0.01% | 0.0% |
| Q2 2017 | $2,078,000 | +38.7% | 34,329 | +18.8% | 0.01% | +80.0% |
| Q1 2017 | $1,498,000 | -59.9% | 28,890 | -65.7% | 0.01% | -64.3% |
| Q4 2016 | $3,734,000 | +629.3% | 84,223 | +682.7% | 0.01% | +600.0% |
| Q3 2016 | $512,000 | +54.7% | 10,760 | +47.1% | 0.00% | +100.0% |
| Q2 2016 | $331,000 | +11.8% | 7,313 | -5.8% | 0.00% | -50.0% |
| Q4 2015 | $296,000 | +41.0% | 7,766 | +21.5% | 0.00% | +100.0% |
| Q3 2015 | $210,000 | -4.1% | 6,394 | +10.9% | 0.00% | 0.0% |
| Q2 2015 | $219,000 | -78.1% | 5,766 | -57.7% | 0.00% | -75.0% |
| Q4 2014 | $999,000 | -2.2% | 13,636 | -3.5% | 0.00% | 0.0% |
| Q2 2014 | $1,021,000 | -35.1% | 14,128 | -33.9% | 0.00% | -33.3% |
| Q1 2014 | $1,574,000 | -18.6% | 21,389 | -23.1% | 0.01% | -25.0% |
| Q4 2013 | $1,934,000 | +114.9% | 27,813 | +103.0% | 0.01% | +100.0% |
| Q3 2013 | $900,000 | -11.2% | 13,704 | -6.3% | 0.00% | -20.0% |
| Q2 2013 | $1,014,000 | – | 14,632 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SECTOR GAMMA AS | 713,500 | $49,895,000 | 12.74% |
| Veritas Asset Management LLP | 7,636,450 | $534,017,000 | 7.53% |
| FIRST NEW YORK SECURITIES LLC /NY | 154,158 | $10,780,269,000 | 5.40% |
| Gabalex Capital Management LLC | 200,000 | $14,981,000 | 5.39% |
| Veritas Investment Management LLP | 291,825 | $18,816,000 | 5.32% |
| Tweedy, Browne Co LLC | 2,543,966 | $177,900,000 | 4.91% |
| York Capital Management Global Advisors, LLC | 8,074,375 | $564,641,000 | 4.78% |
| First Fiduciary Investment Counsel, Inc. | 270,675 | $18,928,000 | 4.10% |
| SCHARF INVESTMENTS, LLC | 2,247,225 | $157,148,000 | 4.03% |
| Osher Van de Voorde Investment Management | 96,235 | $6,730,000 | 3.91% |